세계의 정맥주사(IV) 철분제 시장 규모 조사 및 예측, 제품별, 용도별, 지역별 분석(2023-2030년)

Global Intravenous Iron Drugs Market is valued at approximately USD 2.92 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.6% over the forecast period 2023-2030. Intravenous iron drugs are medications administered directly into the bloodstream to replenish iron stores in the body. They are used when oral iron supplements are ineffective or not suitable. These drugs help treat iron deficiency anemia by rapidly increasing iron levels in the body. The rising prevalence of chronic kidney disease, inflammatory bowel disease, and cancer, which are important indications for intravenous iron usage, is a significant driver for market growth. Additionally, the growing incidence of infectious diseases such as malaria, HIV/AIDS, TB, hepatitis, pneumonia, and influenza is expected to increase the demand for intravenous drugs in the future.

Moreover, the growing prevalence of cancer can support the growth of the Intravenous Iron Drugs Market. According to the WHO in 2022, Cancer, responsible for nearly 10 million deaths in 2020, remains a prominent global cause of mortality. In terms of new cases of cancer in 2020, the following were the most prevalent: Breast cancer accounted for 2.26 million cases, followed by lung cancer with 2.21 million cases, colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, non-melanoma skin cancer with 1.20 million cases, and stomach cancer with 1.09 million cases in 2020. Additionally, an growing investment in drugs development is anticipated to create the lucrative opportunity for the market during forecast period. However, adverse reactions associated with intravenous iron drugs stifling market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Intravenous Iron Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing prevalence of chronic kidney disease, gastrointestinal illnesses, and cancers in the region. Asia Pacific is expected to grow at fastest growth rate during the forecast period, owing to supportive government initiatives and the development of healthcare infrastructure. In addition, the high incidence of chronic kidney disease in developing nations such as China and India have aided market growth.

Major market player included in this report are:

• CSL Limited
• Covis Pharma GmbH
• Daiichi Sankyo Company, Ltd.
• Sanofi S.A.
• Pharma cosmos A/S
• Shield Therapeutics Plc
• AbbVie Inc.
• Rockwell Medical Inc
• Americal Reagent Inc
• Pfizer Inc.

Recent Developments in the Market:

• In November 2022, Fer inject an intravenous iron therapy, obtained approval from China's National Medical Products Administration (NMPA). This approval allows CSL Vifor and Fresenius Kabi to utilize Fer inject for treating iron deficiency in adult patients who are unresponsive to oral iron preparations, unable to use them, or require rapid iron delivery due to clinical necessity.
• In November 2022, a group of researchers funded by the National Institutes of Health (NIH) initiated a study to investigate the effectiveness of intravenous iron drug treatment for women with post-pregnancy anemia. The study aims to enrol approximately 5,000 women across multiple countries, including India, Bangladesh, Pakistan, the Democratic Republic of Congo, Kenya, Zambia, and Guatemala.

Global Intravenous Iron Drugs Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Application, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Iron Sucrose
• Iron Dextran
• Ferric Carboxymaltose
• Others

By Application:

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Intravenous Iron Drugs Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Intravenous Iron Drugs Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Intravenous Iron Drugs Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Intravenous Iron Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Intravenous Iron Drugs Market Dynamics

• 3.1. Intravenous Iron Drugs Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising Incidences of Chronic Kidney Disease
    • 3.1.1.2. Growing incidence of infectious diseases
  • 3.1.2. Market Challenges
    • 3.1.2.1. Adverse reactions associated with intravenous iron drugs
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing investment in drugs development

Chapter 4. Global Intravenous Iron Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Intravenous Iron Drugs Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Intravenous Iron Drugs Market by Product, Performance - Potential Analysis
• 5.3. Global Intravenous Iron Drugs Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Intravenous Iron Drugs Market, Sub Segment Analysis
  • 5.4.1. Iron Sucrose
  • 5.4.2. Iron Dextran
  • 5.4.3. Ferric Carboxymaltose
  • 5.4.4. Others

Chapter 6. Global Intravenous Iron Drugs Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Intravenous Iron Drugs Market by Application, Performance - Potential Analysis
• 6.3. Global Intravenous Iron Drugs Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Intravenous Iron Drugs Market, Sub Segment Analysis
  • 6.4.1. Chronic Kidney Disease
  • 6.4.2. Inflammatory Bowel Disease
  • 6.4.3. Cancer
  • 6.4.4. Others

Chapter 7. Global Intravenous Iron Drugs Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Intravenous Iron Drugs Market, Regional Market Snapshot
• 7.4. North America Intravenous Iron Drugs Market
  • 7.4.1. U.S. Intravenous Iron Drugs Market
    • 7.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Application breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Intravenous Iron Drugs Market
• 7.5. Europe Intravenous Iron Drugs Market Snapshot
  • 7.5.1. U.K. Intravenous Iron Drugs Market
  • 7.5.2. Germany Intravenous Iron Drugs Market
  • 7.5.3. France Intravenous Iron Drugs Market
  • 7.5.4. Spain Intravenous Iron Drugs Market
  • 7.5.5. Italy Intravenous Iron Drugs Market
  • 7.5.6. Rest of Europe Intravenous Iron Drugs Market
• 7.6. Asia-Pacific Intravenous Iron Drugs Market Snapshot
  • 7.6.1. China Intravenous Iron Drugs Market
  • 7.6.2. India Intravenous Iron Drugs Market
  • 7.6.3. Japan Intravenous Iron Drugs Market
  • 7.6.4. Australia Intravenous Iron Drugs Market
  • 7.6.5. South Korea Intravenous Iron Drugs Market
  • 7.6.6. Rest of Asia Pacific Intravenous Iron Drugs Market
• 7.7. Latin America Intravenous Iron Drugs Market Snapshot
  • 7.7.1. Brazil Intravenous Iron Drugs Market
  • 7.7.2. Mexico Intravenous Iron Drugs Market
• 7.8. Middle East & Africa Intravenous Iron Drugs Market
  • 7.8.1. Saudi Arabia Intravenous Iron Drugs Market
  • 7.8.2. South Africa Intravenous Iron Drugs Market
  • 7.8.3. Rest of Middle East & Africa Intravenous Iron Drugs Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. CSL Limited
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Covis Pharma GmbH
  • 8.3.3. Daiichi Sankyo Company, Ltd.
  • 8.3.4. Sanofi S.A.
  • 8.3.5. Pharma cosmos A/S
  • 8.3.6. Shield Therapeutics Plc
  • 8.3.7. AbbVie Inc.
  • 8.3.8. Rockwell Medical Inc
  • 8.3.9. Americal Reagent Inc
  • 8.3.10. Pfizer Inc.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption